MEDIPAL HOLDINGS decided on personnel changes effective 1 October at meetings of its Nomination Committee and Board of Directors. Representative Director and President Shuichi Watanabe (渡辺秀一) will become chairman, while Managing Director Kuniaki Imagawa (今川国明), in charge of the pharmaceutical business, will newly become representative director and president.
MEDIPAL HOLDINGS has decided on personnel changes effective 1 October under which Representative Director and President Shuichi Watanabe (渡辺秀一) will become representative director and chairman, while Managing Director Kuniaki Imagawa (今川国明), in charge of the pharmaceutical business, will become representative director and president. Representative Director and Executive Vice President Yasuhiro Chofuku (長福泰弘) will remain in his current position and also assume responsibility for the pharmaceutical business. The new management structure will have 3 representative directors. The company said the changes are intended to enhance corporate value and achieve sustainable growth. Further updates are awaited.
Under personnel changes at MEDICEO, Kuniaki Imagawa (今川国明) will become representative director and chairman, while Director and Head of the Western Japan Branch Osamu Utsumi (内海修) will become representative director and president. Representative Director and Chairman Yasuhiro Chofuku (長福泰弘) will change from director and corporate adviser to corporate adviser, while Watanabe Shuichi (渡辺秀一) is scheduled to change from director and corporate adviser to corporate adviser.